



PALLA PHARMA

ASX ANNOUNCEMENT

Thursday 9 September 2021

Update on lodgement of reviewed half-year financial report

Further to the ASX announcement of 30 August 2021, Palla Pharma Limited (ASX:PAL) ('the Company') today advises that additional time will be required to complete the half-year financial report and allow the Company's auditor sufficient time to complete their review. The Company lodged its unreviewed Appendix 4D and preliminary interim report on 31 August 2021.

As previously indicated, the Company is relying on relief provided by ASIC Corporations (Extended Reporting and Lodgement Deadlines — Listed Entities) Instrument 2020/451, which extends the lodgement deadline for listed entities to lodge their half-yearly reports by allowing up to one additional month.

The Company will provide a further update ahead of the extended deadline if there is a material difference between its previously released Appendix 4D and preliminary interim report, and its reviewed half-year financial report by way of an ASX announcement on the ASX Market Announcements Platform.

This announcement has been authorised for release by the Board of Directors.

For more information please contact:

Simon Moore

Chairman
Palla Pharma Limited
+61 3 9301 0800

Brendan Middleton

Chief Financial Officer
Palla Pharma Limited
+61 3 9301 0800

About Palla Pharma Limited:

Palla Pharma Limited (ASX:PAL) is a vertically integrated opiate manufacturer from poppy straw growing through to tableting production. Palla Pharma has developed an innovative, efficient, and environmentally sustainable opiate manufacturing process based on a unique water-based extraction technology. The company is one of six licensed opiate producers globally, and one of three fully integrated suppliers from opiate extraction through to tableting production delivering on its strategy to secure access to regulated downstream narcotics markets by leveraging its production cost advantage.

Palla Pharma Limited

PO Box 2139 Melbourne, VIC 3001, Australia

T +61 3 9301 0800 / F +61 3 9301 0899 / W pallapharma.com / E info@pallapharma.com